Results 21 to 30 of about 10,001 (276)

Safety and efficacy of continuous terlipressin infusion in HRS-AKI in a transplant population

Liver transplantation
Hepatorenal syndrome-acute kidney injury (HRS-AKI) is associated with significant morbidity and mortality. While liver transplantation is the definitive treatment, continuous terlipressin infusion for HRS-AKI may provide benefit and, as such, was ...
K. Rajender Reddy, Ethan M. Weinberg, Stevan A. Gonzalez, Manhal Izzy, Douglas A. Simonetto, R. Todd Frederick, Raymond A. Rubin, Zachary Fricker, Jade Ikahihifo-Bender, Maggie Harte, Sandra Garcia, Kathryn Campbell, Amy Olofson, Ryan F. Razavi, Janelle M. James, Het Patel, Grace Kim-Lee, Sherry Witkiewicz, William Tobin, Khurram Jamil   +19 more
openalex   +2 more sources

Efficacy and Safety of Terlipressin Infusion in Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI): A Retrospective Observational Study

Cureus
Background Hepatorenal syndrome-acute kidney injury (HRS-AKI) is an event that occurs in chronic liver disease (CLD) and is associated with high morbidity and mortality. Terlipressin, a vasopressin analog, is used for the treatment of portal hypertension-
Manoj Gowda, Dave Manan Dilipbhai, Umesh Jalihal, Madduri Pavan Kumar, Bharath Bharadwaj M S, Anil Jain, Naveen Ganjoo   +6 more
openalex   +2 more sources

Terlipressin in combination with albumin as a therapy for hepatorenal syndrome in patients aged 65 years or older

Annals of Hepatology, 2023
Introduction and Objectives: Clinical data for older patients with advanced liver disease are limited. This post hoc analysis evaluated the efficacy and safety of terlipressin in patients aged ≥65 years with hepatorenal syndrome using data from 3 Phase ...
Muhammad A. Mujtaba, Ann Kathleen Gamilla-Crudo, Shehzad N. Merwat, Syed A. Hussain, Michael Kueht, Aftab Karim, Muhammad W. Khattak, Peggy J. Rooney, Khurram Jamil   +8 more
doaj   +1 more source

Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome

AAPS Open, 2022
The objective of this population pharmacokinetics (PK) analysis was to characterize the PK of terlipressin and its active metabolite, lysine-vasopressin (L-VP), in patients with hepatorenal syndrome (HRS), following intravenous administration of ...
Xiaofeng Wang, Khurram Jamil
doaj   +1 more source

Early treatment with terlipressin in patients with hepatorenal syndrome yields improved clinical outcomes in North American studies

Hepatology Communications, 2023
Hepatorenal syndrome type 1 (HRS-1) is a serious complication of advanced cirrhosis and a potentially reversible form of acute kidney injury that is associated with rapidly deteriorating kidney function.
M. Curry, H. Vargas, A. Befeler, N. Pyrsopoulos, V. Patwardhan, K. Jamil   +5 more
semanticscholar   +1 more source

COMPARISON OF EFFICACY ON NORADRENALINE AND TERLIPRESSIN IN HEPATORENAL SYNDROME IN THE PATIENTS OF DECOMPENSATED CIRRHOSIS – A RANDOMIZED CONTROLLED STUDY

Pakistan Armed Forces Medical Journal, 2019
Objective: To compare the efficacy of noradrenaline and terlipressin in hepatorenal syndrome. Study Design: Randomized controlled trial. Place and Duration of Study: Combined Military Hospital Lahore, from May 2018 to Jan 2019.
Muhammad Siddique, Mansoor Ud Din Sajid, Omar Ahsan   +2 more
doaj   +1 more source

Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study

Scientific Reports, 2022
Terlipressin with albumin, the recommended treatment for hepatorenal syndrome-acute kidney injury (HRS-AKI), is associated with adverse events. Furthermore, the course of AKI in patients with acute-on-chronic liver failure (ACLF) is unknown.
Anand V. Kulkarni, Sowmya Tirumalige Ravikumar, Harshvardhan Tevethia, Madhumita Premkumar, Karan Kumar, Mithun Sharma, Rajesh Gupta, Padaki Nagaraja Rao, Duvvuru Nageshwar Reddy   +8 more
doaj   +1 more source

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence

Canadian Journal of Gastroenterology and Hepatology, 2020
Ascites, a common complication in cirrhosis, is prone to the development of acute kidney injury or hepatorenal syndrome and can be complicated by circulatory dysfunction after paracentesis.
Zhaohui Bai, Yang An, Xiaozhong Guo, Rolf Teschke, Nahum Méndez-Sánchez, Hongyu Li, Xingshun Qi   +6 more
doaj   +1 more source

Addition of terlipressin to norepinephrine in septic shock and effect of renal perfusion: a pilot study

Renal Failure, 2022
Purpose Terlipressin improves renal function in patients with septic shock. However, the mechanism remains unclear. Here, we aimed to evaluate the effects of terlipressin on renal perfusion in patients with septic shock.Materials and Methods This pilot ...
Jinlong Wang, Mengjuan Shi, Lili Huang, Qing Li, Shanshan Meng, Jingyuan Xu, Ming Xue, Jianfeng Xie, Songqiao Liu, Yingzi Huang   +9 more
doaj   +1 more source

Terlipressin— [PDF]

Intensivmedizin und Notfallmedizin, 2005
The vasopressing agent terlipressin is a commonly used drug with various indications especially in patients with advanced cirrhosis. Being a potent vasoconstrictor it increases the systemic vascular pressure especially inthe splanchnic area, resulting in a decrease of portal pressure. Due to complex pathophysiologic patterns, different complications of
T. Brünnler, F. Mandraka, J. Langgartner   +2 more
openaire   +2 more sources